AgomAb Therapeutics NV (AGMB) began trading on the Nasdaq on Fri 6 Feb 26

AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases with a focus on chronic fibrotic indications with unmet medical needs.

• Sector: Healthcare
• Industry: Biotechnology
• Full Time Employees: 57
• Incorporated in 2017 
• Headquartered in Antwerp, Belgium
• https://agomab.com

AgomAb Therapeutics NV opened at $14.70 after pricing a 12.5 mln share IPO at $16.00 per ADS, at the midpoint of the $15-17 expected range